FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Thursday reported a loss of $22.7 million in its fourth quarter.
On a per-share basis, the Fort Myers, Florida-based company said it had a loss of 18 cents. Losses, adjusted for costs related to mergers and acquisitions and stock option expense, were 6 cents per share.
The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 15 cents per share.
The operator of cancer-focused testing laboratories posted revenue of $138.7 million in the period, also beating Street forecasts. Six analysts surveyed by Zacks expected $130 million.
For the year, the company reported that its loss widened to $144.3 million, or $1.16 per share. Revenue was reported as $509.7 million.
NeoGenomics expects full-year results to range from a loss of 38 cents per share to a loss of 32 cents per share.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NEO at https://www.zacks.com/ap/NEO
Copyright © 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.